{"id":31910,"date":"2025-04-16T15:13:50","date_gmt":"2025-04-16T07:13:50","guid":{"rendered":"https:\/\/flcube.com\/?p=31910"},"modified":"2025-04-16T15:13:51","modified_gmt":"2025-04-16T07:13:51","slug":"edwards-lifesciences-gains-eu-ce-mark-for-sapien-m3-mitral-valve-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31910","title":{"rendered":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System"},"content":{"rendered":"\n

US medical device giant Edwards Lifesciences Corporation (NYSE: EW<\/a>) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.<\/p>\n\n\n\n

Innovation and Clinical Evidence<\/strong>
The SAPIEN M3 system is the world\u2019s first transcatheter valve replacement therapy designed to treat mitral regurgitation using a transfemoral approach. Clinical studies have demonstrated its effectiveness in reducing MR and improving patients\u2019 quality of life. The therapy offers a new option for patients who previously had limited treatment choices due to surgical or TEER ineligibility.<\/p>\n\n\n\n

Post-Market Surveillance<\/strong>
Edwards Lifesciences plans to initiate a five-year post-market clinical follow-up study to evaluate the SAPIEN M3 system in real-world settings. This study will provide additional data on the long-term safety and efficacy of the device, further supporting its use in clinical practice.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received…<\/p>\n","protected":false},"author":1,"featured_media":31911,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[69,245,4002,15],"class_list":["post-31910","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-cvd","tag-edwards-lifesciences","tag-nyse-ew","tag-product-approvals"],"yoast_head":"\nEdwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31910\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System\" \/>\n<meta property=\"og:description\" content=\"US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31910\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T07:13:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T07:13:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System\",\"datePublished\":\"2025-04-16T07:13:50+00:00\",\"dateModified\":\"2025-04-16T07:13:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910\"},\"wordCount\":184,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1609.webp\",\"keywords\":[\"CVD\",\"Edwards Lifesciences\",\"NYSE: EW\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31910#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31910\",\"name\":\"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1609.webp\",\"datePublished\":\"2025-04-16T07:13:50+00:00\",\"dateModified\":\"2025-04-16T07:13:51+00:00\",\"description\":\"US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31910\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1609.webp\",\"width\":1080,\"height\":608,\"caption\":\"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31910#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System - Insight, China's Pharmaceutical Industry","description":"US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31910","og_locale":"en_US","og_type":"article","og_title":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System","og_description":"US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.","og_url":"https:\/\/flcube.com\/?p=31910","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-16T07:13:50+00:00","article_modified_time":"2025-04-16T07:13:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31910#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31910"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System","datePublished":"2025-04-16T07:13:50+00:00","dateModified":"2025-04-16T07:13:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31910"},"wordCount":184,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31910#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp","keywords":["CVD","Edwards Lifesciences","NYSE: EW","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31910#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31910","url":"https:\/\/flcube.com\/?p=31910","name":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31910#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31910#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp","datePublished":"2025-04-16T07:13:50+00:00","dateModified":"2025-04-16T07:13:51+00:00","description":"US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received the CE mark in the European Union (EU) for its SAPIEN M3 mitral valve replacement system. This approval allows the device to be used for transcatheter treatment of patients with symptomatic moderate-to-severe or severe mitral regurgitation (MR) who are not candidates for surgery or transcatheter edge-to-edge (TEER) therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31910#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31910"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31910#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp","width":1080,"height":608,"caption":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31910#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1609.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31910"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31910\/revisions"}],"predecessor-version":[{"id":31912,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31910\/revisions\/31912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31911"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}